• Levamisole hydrochloride, a nonspecific immunostimulant, was given to 30 children with atopic dermatitis (AD) in a double-blind manner during an eightmonth period. Clinical course findings, including intradermal reactions to tuberculin, candidin, and streptokinase-streptodornase; sensitization to dinitrochlorobenzene; peripheral blood T- and Blymphocytes; in vitro lymphocyte transformation with phytohemagglutinin; and serum levels of IgM, IgG, IgA, and IgE, were noted every two months. Fifteen children completed the study. Neither the clinical course nor the immunologic values showed substantial differences between the levamisole-treated and the placebo group. Our experience with levamisole in AD is disappointing.
(Arch Dermatol 114:1316-1319, 1978)
Alomar A, Giménez-Camarasa JM, de Moragas JM. The Use of Levamisole in Atopic Dermatitis: A Prospective Study. Arch Dermatol. 1978;114(9):1316–1319. doi:10.1001/archderm.1978.01640210011003
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: